Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Purple Biotech ( (PPBT) ) just unveiled an update.
On February 25, 2026, Purple Biotech announced it will change the ratio of its American Depositary Shares to ordinary shares from 1:200 to 1:2,000, effectively a one-for-ten reverse ADS split. The revised ADSs are expected to begin trading on or about March 2, 2026, on Nasdaq under the existing ticker PPBT but with a new CUSIP, while the company’s Tel Aviv–listed ordinary shares remain unaffected by the move.
The primary goal of the ADS ratio change is to lift the ADS trading price to help Purple Biotech regain compliance with Nasdaq’s $1.00 minimum bid requirement and improve the suitability of its securities for continued trading. Fractional ADS entitlements will be aggregated and sold for cash by the depositary, and the company expects the ADS price to rise proportionally, though it cautions there is no assurance the increase will match the tenfold ratio adjustment.
The most recent analyst rating on (PPBT) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page.
Spark’s Take on PPBT Stock
According to Spark, TipRanks’ AI Analyst, PPBT is a Neutral.
The score is held down primarily by the lack of revenue, ongoing losses, and negative free cash flow, indicating continued reliance on external funding. Technical indicators also point to a bearish trend with weak momentum. The main positive is the low-debt balance sheet, which reduces near-term leverage risk but does not offset weak operating fundamentals.
To see Spark’s full report on PPBT stock, click here.
More about Purple Biotech
Purple Biotech Ltd. is a clinical-stage oncology company developing first-in-class immunotherapies aimed at overcoming tumor immune evasion and drug resistance. Its lead CAPTN-3 platform uses capped tri-specific antibodies to target tumors while engaging T cells and NK cells, alongside pipeline assets CM24 for pancreatic cancer and NT219 for head and neck cancer.
Average Trading Volume: 314,891
Technical Sentiment Signal: Sell
Current Market Cap: $5.99M
For a thorough assessment of PPBT stock, go to TipRanks’ Stock Analysis page.